BBOT
BridgeBio Oncology Therapeutics, Inc.Company Information
- Company Name
- BridgeBio Oncology Therapeutics, Inc.
- CIK
- CIK0001869105
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- BBOT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BBOT
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-02-13
- Last sale
- —
- Shares purchased (TTM)
- 2,400,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 59,115,292
- Shares outstanding
- 80,054
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -2.39%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | - | - | - | - | 0 | 0 | 0 | - | - | - | ||||||
| Preferred Stock | -0 | 0 | 0 | -39 | 39 | 0 | 23 | 36 | - | - | ||||||
Assets | ||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 54 | 53 | 374 | 409 | 1 | 1 | 31 | 2 | 2 | 2 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Prepaid Taxes | - | - | - | - | - | 0 | 0 | 0 | - | - | ||||||
| Marketable Securities Current | 172 | 200 | 52 | 60 | - | - | 125 | - | - | - | ||||||
| Accounts And Other Receivables Net Current | 1 | 0 | 0 | - | - | - | 0 | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 16 | 14 | 7 | 7 | 0 | - | 3 | - | - | - | ||||||
| Prepaid Insurance | - | - | - | - | 0 | 0 | 0 | 0 | - | - | ||||||
| Assets Current | 242 | 267 | 432 | 476 | 1 | 1 | 159 | 2 | 2 | 2 | ||||||
| Prepaid Expense Noncurrent | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Assets Held In Trust Noncurrent | - | - | - | - | 197 | 194 | 192 | 190 | 188 | 185 | ||||||
| Marketable Securities Noncurrent | 118 | 137 | - | - | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | - | - | 0 | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 2 | - | - | 0 | - | - | - | ||||||
| Other Assets Noncurrent | 13 | 11 | 13 | 5 | - | - | 5 | - | - | - | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | ||||||
| Assets | 377 | 418 | 448 | 485 | 197 | 196 | 164 | 192 | 190 | 188 | ||||||
| Accounts Payable And Accrued Liabilities Current | - | - | - | - | 3 | - | - | - | - | - | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||
| Accrued Liabilities Current | - | - | - | - | - | 2 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||
| Accounts Payable Current | 7 | 12 | 1 | 4 | - | - | 3 | - | - | - | ||||||
| Accrued Employee Benefits Current | 4 | 2 | 6 | 4 | - | - | 4 | - | - | - | ||||||
| Accrued Professional Fees Current | 2 | 1 | 1 | 2 | - | - | 1 | - | - | - | ||||||
| Notes Payable Current | - | 1 | 1 | 1 | - | - | 0 | - | - | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | - | - | 0 | - | - | - | ||||||
| Other Accrued Liabilities Current | 0 | 1 | 0 | 0 | - | - | 0 | - | - | - | ||||||
| Participating Mortgage Loans Participation Liabilities Amount | - | - | 0 | - | - | - | 3 | - | - | - | ||||||
| Liabilities Current | 52 | 43 | 35 | 36 | 3 | 2 | 20 | 0 | 0 | 0 | ||||||
| Deferred Compensation Liability Classified Noncurrent | - | - | - | - | - | - | - | - | - | 6 | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 2 | 2 | - | - | 0 | - | - | - | ||||||
| Liabilities | 54 | 45 | 37 | 38 | 8 | 7 | 20 | 6 | 6 | 6 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | - | 185 | ||||||
Stockholders Equity | ||||||||||||||||
| Common Class B | - | - | - | - | 0 | 5 | 0 | 0 | 0 | 5 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | - | - | 0 | - | - | 0 | ||||||
| Additional Paid In Capital | 779 | 772 | 768 | 764 | - | - | 44 | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -455 | -399 | -357 | -318 | -7 | -6 | -223 | -4 | -3 | -3 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | 0 | 0 | - | - | 0 | - | - | - | ||||||
| Stockholders Equity | 323 | 372 | 411 | 447 | -228 | -200 | -179 | -159 | -3 | -3 | ||||||
| Liabilities And Stockholders Equity | 377 | 418 | 448 | 485 | 197 | 196 | 164 | 192 | 190 | 188 | ||||||
| Common Class A | - | - | - | - | 0 | 19 | 18 | 18 | 0 | 1 | ||||||
| Redeemable Convertible Preferred Stock | 0 | 0 | 0 | -39 | 3 | 36 | 36 | 36 | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 5 | 5 | 0 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 | - | - | - | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | - | - | 41 | - | - | - | ||||||
| Common Stock Shares Issued | 80 | 80 | 80 | 79 | - | - | 28 | - | - | - | ||||||
| Shares Outstanding | 80 | 80 | 80 | 79 | - | - | 28 | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBridgeBio Oncology Therapeutics, Inc. (BBOT) — SEC Financial Statements & Analysis
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a pharmaceutical preparations company, incorporated in DE. BridgeBio Oncology Therapeutics, Inc. trades on Nasdaq as: BBOT. BridgeBio Oncology Therapeutics, Inc. (BBOT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, BridgeBio Oncology Therapeutics, Inc. carries a market cap of $610.01K, a P/E ratio of -0.00x, a P/B ratio of 0.00x, a P/S ratio of 0.04x, an enterprise value of $-53.58M, and an EV/EBITDA multiple of 0.27x. On profitability, it posts an operating margin of -1295.03%, a net margin of -1185.41%, a Return on Equity (ROE) of -381.87%, a Return on Assets (ROA) of -63.44%, and a Return on Invested Capital (ROIC) of -3963.92%. Per share, it reports EPS of $-2274.89, diluted EPS of $-2274.89, free cash flow per share of $-1893.27, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 55.94% year-over-year, net income growth of 42.19% year-over-year, and EPS growth of 89060.45% year-over-year. On the balance sheet, it maintains a current ratio of 4.69x, a quick ratio of 4.38x, working capital of $190.74M, a debt-to-equity ratio of 0.17x, a debt ratio of 0.14, free cash flow of $-151.56M (TTM), and net debt of $-54.20M. Figures sourced from SEC EDGAR.
- Market Cap
- $610.01K
- P/E TTM
- -0.00x
- EPS TTM
- $-2274.89
- P/B TTM
- 0.00x
- ROE TTM
- -381.87%
- ROA TTM
- -63.44%
- Debt To Equity
- 0.17x
- Free Cash Flow TTM
- $-151.56M
- Net Revenue TTM Growth 1Y
- 55.94%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BridgeBio Oncology Therapeutics, Inc. in?
BridgeBio Oncology Therapeutics, Inc. (BBOT) operates in the Pharmaceutical Preparations industry.
What exchange does BBOT trade on?
BridgeBio Oncology Therapeutics, Inc. (BBOT) trades on the Nasdaq.
Where is BridgeBio Oncology Therapeutics, Inc. incorporated?
BridgeBio Oncology Therapeutics, Inc. is incorporated in DE.
When was BridgeBio Oncology Therapeutics, Inc. (BBOT)'s most recent SEC filing?
BridgeBio Oncology Therapeutics, Inc. (BBOT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is BBOT's market cap?
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a market capitalization of $610.01K as of 2026-06-30.
What is BBOT's EPS (earnings per share)?
BridgeBio Oncology Therapeutics, Inc. (BBOT)'s trailing twelve month EPS is $-2274.89 as of 2026-06-30.
What is BBOT's ROE (return on equity)?
BridgeBio Oncology Therapeutics, Inc. (BBOT)'s trailing twelve month Return on Equity (ROE) is -381.87% as of 2026-06-30.
What is BBOT's ROA (return on assets)?
BridgeBio Oncology Therapeutics, Inc. (BBOT)'s trailing twelve month Return on Assets (ROA) is -63.44% as of 2026-06-30.
What is BBOT's ROIC (return on invested capital)?
BridgeBio Oncology Therapeutics, Inc. (BBOT)'s trailing twelve month Return on Invested Capital (ROIC) is -3963.92% as of 2026-06-30.
What is BBOT's EV/EBITDA?
BridgeBio Oncology Therapeutics, Inc. (BBOT)'s trailing twelve month EV/EBITDA is 0.27x as of 2026-06-30.